Dermtech, INC 8-K filings

DermTech, Inc. will be delisted from the Nasdaq Capital Market after filing for Chapter 11 bankruptcy.

DermTech has filed for Chapter 11 bankruptcy protection and is reducing its workforce by approximately 20% as part of a strategic restructuring.

DermTech is being sued by its landlord for $661,706.34 in unpaid rent, potentially impacting the company's financial stability.

DermTech's first-quarter 2024 results show increased revenue and reduced losses, driven by higher average selling prices and cost-cutting measures.

DermTech, Inc. has received a notice of potential default on its office lease due to $661,706 in unpaid rent, which could have a material adverse effect on the company's finances.

DermTech is implementing a restructuring plan, including a 56% workforce reduction, while exploring strategic alternatives to maximize stockholder value.

DermTech has received a notice from Nasdaq stating that its stock price has fallen below the required minimum of $1.00 per share for continued listing.

DermTech's Q4 2023 results show a significant increase in test revenue and average selling price, alongside reduced operating expenses, positioning the company for a longer cash runway.

DermTech is implementing a restructuring plan, including a 15% workforce reduction, to focus on revenue growth and reduce operating expenses by $40 million compared to fiscal year 2022.